Vnitr Lek 2018, 64(9):834-838 | DOI: 10.36290/vnl.2018.114

Pathophysiology, causes and epidemiology of chronic heart failure

Jindřich ©pinar1,*, Lenka ©pinarová2, Jiří Vítovec2
1 Interní kardiologická klinika LF MU a FN Brno, pracoviątě Bohunice
2 I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně

The prevalence of heart failure in developed countries is about 1-2 % in general and in patients above 70 years over 10 %. HFpEF is the cause of heart failure from 22 to 73 %, exact data are not available. If compared with HFrEF, patients with HFpEF are older, more frequent women with hypertension and atrial fibrillation, but less myocardial infarction in their history. Heart failure is a hemodynamic disorder and the pathophysiologic basis is cardiac output, cardiac contractility, filling pressures, wall stress during systolic and diastolic function and heart rate. The neurohumoral activation is very important for the diagnosis as well as prognosis and the most sensitive seems to be brain natriuretic peptide (BNP), respectively the precursor NT-proBNP, which become a part of the new diagnostic classification and are a part of modern treatment.

Keywords: heart failure; hemodynamics; neurohumoral activation

Received: July 18, 2018; Accepted: August 13, 2018; Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, ©pinarová L, Vítovec J. Pathophysiology, causes and epidemiology of chronic heart failure. Vnitr Lek. 2018;64(9):834-838. doi: 10.36290/vnl.2018.114.
Download citation

References

  1. Ponikowski P, Voors AA, Anker SD et al. [ESC Scientific Document Group]. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>. Erratum in Erratum. [Eur Heart J. 2018]. Go to original source... Go to PubMed...
  2. Antman EM, Bax J, Chazal RA. Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. Eur Heart J. 2016; 37(27): 2096. Dostupné z DOI: <http://doi:10.1093/eurheartj/ehw219>. Go to original source... Go to PubMed...
  3. ©pinar J, Hradec J, ©pinarová L et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of cardiology. Cor Vasa 2016; 58(5): e530-e568. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crvasa.2016.09.004>. Go to original source...
  4. ©pinar J, Hradec J, ©pinarová L et al. Souhrn doporučených postupů ESC pro diagnózu a léčbu akutního a chronického srdečního selhání z roku 2016. Připraven Českou kardiologickou společností. Cor et Vasa 2016; 58(5): 455-494. Go to original source...
  5. ©pinar J, ©pinarová L. Chronické srdeční selhání. In: Táborský M. Novinky v kardiologii. Mladá fronta: Praha 2015: 212-229. ISBN 978-80-204-3712-9.
  6. Tanai E, Frantz S. Pathophysiology of Heart Failure. Compr Physiol 2015; 6(1): 187-214. Dostupné z DOI: <http://dx.doi.org/10.1002/cphy.c140055>. Go to original source... Go to PubMed...
  7. Widimský J, Lefflerová K, Sedlacek K. Srdeční selhání. 4. vyd. Triton: Praha 2013. ISBN 978-80-7387-680-7.
  8. Petrie MC, McClure SJ, Love MP et al. Novel neuropeptide in the pathophysiology of heart failure:adrenomedullin and endothelin-1. Eur J Heart Failure 1999; 1(1): 25-29. Dostupné z DOI: <http://dx.doi.org/10.1016/S1388-9842(98)00013-0>. Go to original source... Go to PubMed...
  9. ©pinarová L, Toman J, Pospíąilová J et al. Humoral response in patients with chronic heart failure. Int J Cardiol 1998; 65(3): 227-232. Go to original source... Go to PubMed...
  10. Pacher R, Stanek B, Huelsman M et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27(3): 633-641. Go to original source... Go to PubMed...
  11. Kim HN, Januzzi JL. Natriuretic Peptide Testing in Heart Failure. Circulation 2011; 123(18): 2015-2019. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.979500>. Go to original source... Go to PubMed...
  12. Cheng V, Kazanegra R, Garcia A et al. A Rapid Bedside Test for B-Type Peptide Predicts Treatment Outcomes in Patients Admitted for Decompensated Heart Failure: A Pilot Study. J Am Coll Cardiol 2001; 37(2): 386-391. Go to original source... Go to PubMed...
  13. Maeda K, Tsutamoto T, Wada A et al. High Levels of Plasma Brain Natriuretic Peptide and Interleukin-6 After Optimized Treatment for Heart Failure Are Independent Risk Factors for Morbidity and Mortality in Patients With Congestive Heart Failure. J Am Coll Cardiol 2000; 36(5): 1587-1593. Go to original source... Go to PubMed...
  14. ©pinarová L, ©pinar J, Vítovec J Mají natriuretické peptidy novou ąanci v léčbě srdečního selhání? Vnitř Lék 2014; 60(12): 1076-1080. Go to PubMed...
  15. Vítovec J, ©pinar J, ©pinarová L. Inhibice systému renin-angiotensin-aldosteron u srdečního selhání aneb od obecného souhlasu (CONSENSUS) po vzorec myąlení (PARADIGM-HF). Vnitř Lék 2015; 61(5): 470-474. Go to PubMed...
  16. ©pinarová L, ©pinarová M, Goldbergová-Pávková M et al. Prognostic impact of copeptin and mid-regional pro-adrenomedullin in chronic heart failure with regard to comorbidities. Cardiovasc Dis Diagn 2018; 6(4): 326. Dostupné z DOI: <http://dx.doi.org/10.4172/2329-9517.1000326. Go to original source...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.